Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AQP1 | P29972 | 3/20 | 0.39 |
| ▸ | HTR2A | P28223 | 3/20 | 0.32 |
| ▸ | HTR2C | P28335 | 3/20 | 0.32 |
| ▸ | HTR2B | P41595 | 3/20 | 0.32 |
| ▸ | HTR1A | P08908 | 2/20 | 0.30 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3216316 | 1.00 | AQP1 (0.39) | AQP1HTR2AHTR2CHTR2BHTR1A | |
| SCHEMBL3215986 | 1.00 | AQP1 (0.39) | AQP1HTR2AHTR2CHTR2BHTR1A | |
| SCHEMBL3199334 | 0.90 | AQP1 (0.44) | AQP1HTR2AHTR2CHTR2BSLC6A4 | |
| SCHEMBL3207621 | 0.90 | AQP1 (0.44) | AQP1HTR2AHTR2CHTR2BSLC6A4 | |
| SCHEMBL3213722 | 0.90 | AQP1 (0.44) | AQP1HTR2AHTR2CHTR2BSLC6A4 | |
| SCHEMBL3207423 | 0.89 | AQP1 (0.33) | AQP1HTR1ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3213199 | 0.89 | AQP1 (0.33) | AQP1HTR1ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3204611 | 0.89 | AQP1 (0.33) | AQP1HTR1ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3214385 | 0.89 | AQP1 (0.48) | AQP1 | |
| SCHEMBL3208439 | 0.88 | AQP1 (0.41) | AQP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100035871-A1 | BENZOXAZINE DERIVATIVES AND USES THEREOF | WYETH | 2010-02-11 | — | — | US | claimed |
| US-20100035871-A1 | BENZOXAZINE DERIVATIVES AND USES THEREOF | WYETH | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035871-A1 | BENZOXAZINE DERIVATIVES AND USES THEREOF | HTR2C, HTR5A, NPY1R | AQP1 2125/4885HTR2A 5/4885HTR2C 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.